Generic Name and Formulations:
Mesalamine 1.2g; del-rel tabs.
Shire US, Inc.
Indications for LIALDA:
To induce remission in active, mild-to-moderate ulcerative colitis; and to maintain remission of ulcerative colitis.
≥18yrs: Swallow whole with a meal. 2.4–4.8g once daily for up to 8 weeks. Maintenance: 2.4g once daily.
<18yrs: not established.
Sulfasalazine allergy. Upper GI tract obstruction (eg, pyloric stenosis) may delay onset of action. Discontinue if acute intolerance syndrome is suspected. Conditions predisposing to myocarditis or pericarditis. Atopic dermatitis or eczema: may have more severe photosensitivity reactions. Renal or hepatic impairment. Monitor renal function prior to and periodically during therapy. Elderly (monitor CBCs). Pregnancy (Cat.B). Nursing mothers.
Increased toxicity with nephrotoxic drugs (eg, NSAIDs). Increased risk of blood disorders with azathioprine or 6-mercaptopurine. May cause elevated test results in measuring urinary normetanephrine.
Ulcerative colitis, headache, flatulence, abnormal LFTs, abdominal pain; acute intolerance syndrome (cramping, bloody diarrhea, fever, headache, rash), renal impairment, cardiac hypersensitivity reactions, pancreatitis (rare).